title: Surgery in small cell lung cancer: when and why.
abstract: Small cell lung cancer (SCLC) is considered a systemic disease at diagnosis, because the potential for hematogenous and lymphogenic metastases is very high. For many years, the diagnosis of SCLC was considered a contraindication for surgery because radiotherapy was at least equivalent in terms of local control, and the rate of resectability in SCLC patients was poor. When chemotherapy became the mainstay of treatment for SCLC, radiotherapy was its logical complement, and surgery was progressively abandoned. However, some centers continued to support surgery because experience suggested that in selected patients it was possible to achieve a long-term survival. In the search for predictors of long-term survival it became evident that the TNM staging system was effective for SCLC. The rationale for surgery in the context of SCLC is based on 3 factors: a) Several historical series of patients operated for limited-stage SCLC reported some long-term survivors, showing that cure could be achieved. b) After chemotherapy and radiotherapy, the rate of local relapse is 20%-30%. The assumption that surgical resection might be superior for local disease control has been suggested but not yet proved. c) The surgical intervention can precisely assess pathological (p) response to chemotherapy, identify carcinoids erroneously diagnosed as SCLC, and treat the non-small cell lung cancer (NSCLC) component of tumors with a mixed histology. Even if some controversies exist, it is accepted that surgery can be proposed as the first treatment in patients with T1 or T2 lesions with no evidence of lymph node involvement, followed by adjuvant chemotherapy. In more advanced stages of disease, chemotherapy should be the first step of treatment and surgery can be proposed to responding patients, before radical radiotherapy, depending on the p-stage of disease. Such an intensive multidisciplinary approach should be always employed in the context of controlled clinical trials.
authors.affiliation: Department of Thoracic Surgery, „Metaxa” Cancer Hospital, Piraeus, Greece.
authors.forename: N
authors.initials: N
authors.lastname: Baltayiannis
authors.forename: N
authors.initials: N
authors.lastname: Bolanos
authors.forename: D
authors.initials: D
authors.lastname: Anagnostopoulos
authors.forename: P
authors.initials: P
authors.lastname: Sfyridis
authors.forename: E
authors.initials: E
authors.lastname: Georgiannakis
authors.forename: P
authors.initials: P
authors.lastname: Zografos
authors.forename: A
authors.initials: A
authors.lastname: Chatzimichalis